A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse

Journal of Drug Targeting

Volumn 20, Issue 10, 2012, Pages 873-882

  Maitani, Yoshie ^a   Saito, Hiroshi ^a   Seishi, Yuki ^a   Iwase, Yuko ^a   Yamauchi, Takayasu ^a   Higashiyama, Kimio ^a   Sugino, Takashi ^b  

^a HOSHI UNIVERSITY   (Japan)

^b FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

combination therapy; irinotecan; liposomes; Pheochromocytoma; sunitinib

Indexed keywords

IRINOTECAN; LIPOSOME; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG TARGETING; FEMALE; IMMUNOHISTOCHEMISTRY; LIFESPAN; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; IMMUNOHISTOCHEMISTRY; INDOLES; LIPOSOMES; MICE; MICE, NUDE; PC12 CELLS; PYRROLES; RATS; TISSUE DISTRIBUTION;

EID: 84868340593     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2012.723215     Document Type: Article

References (33)

1. Adams VR, Leggas M. (2007). Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther, 29, 1338-1353. (Pubitemid 47348120)
2. Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. (1988). Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med, 109, 267-273.
3. Blanchet B, Saboureau C, Benichou AS, Billemont B, Taieb F, Ropert S, Dauphin A, Goldwasser F, Tod M. (2009). Development and validation of an HPLC-UV-visible method for sunitinib quantification in human plasma. Clin Chim Acta, 404, 134-139.
4. Chow LQ, Eckhardt SG. (2007). Sunitinib: From rational design to clinical efficacy. J Clin Oncol, 25, 884-896. (Pubitemid 350002890)
5. Ciomei M, Croci V, Ciavolella A, Ballinari D, Pesenti E. (2006). Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin Cancer Res, 12, 2856-2861.
6. Couvelard A, O'Toole D, Turley H, Leek R, Sauvanet A, Degott C, Ruszniewski P, Belghiti J, Harris AL, Gatter K, Pezzella F. (2005). Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: Negative correlation of microvascular density and VEGF expression with tumour progression. Br J Cancer, 92, 94-101. (Pubitemid 40188441)
7. Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P. (2009). Effects of sunitinib on tumor hemodynamics and delivery of chemotherapy. Int J Cancer, 124, 1293-1300.
8. Folkman J. (1972). Anti-angiogenesis: New concept for therapy of solid tumors. Ann Surg, 175, 409-416.
9. Gross DJ, Reibstein I, Weiss L, Slavin S, Dafni H, Neeman M, Pines M, Nagler A. (2003). Treatment with halofuginone results in marked growth inhibition of a von Hippel-Lindau pheochromocytoma in vivo. Clin Cancer Res, 9, 3788-3793. (Pubitemid 37169249)
10. Hattori Y, Shi L, Ding W, Koga K, Kawano K, Hakoshima M, Maitani Y. (2009). Novel irinotecan-loaded liposome using phytic acid with high therapeutic efficacy for colon tumors. J Control Release, 136, 30-37.
11. Haznedar JO, Patyna S, Bello CL, Peng GW, Speed W, Yu X, Zhang Q, Sukbuntherng J, Sweeny DJ, Antonian L, Wu EY. (2009). Singleand multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: Comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol, 64, 691-706.
12. Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN, Teh BT. (2010). Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res, 70, 1053-1062.
13. Huynh H, Ngo VC, Choo SP, Poon D, Koong HN, Thng CH, Toh HC, Zheng L, Ong LC, Jin Y, Song IC, Chang AP, Ong HS, Chung AY, Chow PK, Soo KC. (2009). Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Curr Cancer Drug Targets, 9, 738-747.
14. Iwase Y, Maitani Y. (2011). Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Mol Pharm, 8, 330-337.
15. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. (2009). Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: Targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab, 94, 386-391.
16. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. (2008). Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int J Pharm, 360, 219-224.
17. Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y, Zhang L, Huang RJ, Lu WL. (2011). All-trans retinoic acid stealth liposomes prevent the relapse of breast cancer arising from the cancer stem cells. J Control Release, 149, 281-291.
18. Ma J, Chen CS, Blute T, Waxman DJ. (2011). Antiangiogenesis enhances intratumoral drug retention. Cancer Res, 71, 2675-2685.
19. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release, 65, 271-284. (Pubitemid 30122932)
20. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res, 9, 327-337. (Pubitemid 36109749)
21. Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. (2004). The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis, 7, 225-233.
22. Park KS, Lee JL, Ahn H, Koh JM, Park I, Choi JS, Kim YR, Park TS, Ahn JH, Lee DH, Kim TW, Lee JS. (2009). Sunitinib, a novel therapy for anthracycline-and cisplatin-refractory malignant pheochromocytoma. Jpn J Clin Oncol, 39, 327-331.
23. Pinto AC, Moreira JN, Simões S. (2011). Liposomal imatinibmitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer. Prostate, 71, 81-90.
24. Ramsay EC, Anantha M, Zastre J, Meijs M, Zonderhuis J, Strutt D, Webb MS, Waterhouse D, Bally MB. (2008). Irinophore C: A liposome formulation of irinotecan with substantially improved therapeutic efficacy against a panel of human xenograft tumors. Clin Cancer Res, 14, 1208-1217. (Pubitemid 351302570)
25. Salmenkivi K, Heikkilä P, Liu J, Haglund C, Arola J. (2003). VEGF in 105 pheochromocytomas: Enhanced expression correlates with malignant outcome. APMIS, 111, 458-464. (Pubitemid 36735003)
26. Santarpia L, Habra MA, Jiménez C. (2009). Malignant pheochromocytomas and paragangliomas: Molecular signaling pathways and emerging therapies. Horm Metab Res, 41, 680-686.
27. Strock CJ, Park JI, Rosen DM, Ruggeri B, Denmeade SR, Ball DW, Nelkin BD. (2006). Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab, 91, 79-84. (Pubitemid 43069121)
28. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C. (2003). Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and plateletderived growth factor receptor tyrosine kinase. J Med Chem, 46, 1116-1119. (Pubitemid 36428215)
29. Takemoto S, Yamaoka K, Nishikawa M, Takakura Y. (2006). Histogram analysis of pharmacokinetic parameters by bootstrap resampling from one-point sampling data in animal experiments. Drug Metab Pharmacokinet, 21, 458-464.
30. Tardi PG, Dos Santos N, Harasym TO, Johnstone SA, Zisman N, Tsang AW, Bermudes DG, Mayer LD. (2009). Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther, 8, 2266-2275.
31. Zhang L, Smith KM, Chong AL, Stempak D, Yeger H, Marrano P, Thorner PS, Irwin MS, Kaplan DR, Baruchel S. (2009). In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia, 11, 426-435.
32. Zielke A, Middeke M, Hoffmann S, Colombo-Benkmann M, Barth P, Hassan I, Wunderlich A, Hofbauer LC, Duh QY. (2002). VEGFmediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery, 132, 1056-63; discussion 1063. (Pubitemid 36026955)
33. Zucker D, Barenholz Y. (2010). Optimization of vincristine-topotecan combination-paving the way for improved chemotherapy regimens by nanoliposomes. J Control Release, 146, 326-333.